Clopidogrel should be considered as the first-choice antithrombotic therapy in patients with symptomatic peripheral arterial disease.

After peripheral revascularization procedures, acetylsalicylic acid plus low-dose rivaroxaban could be considered for the long-term (> 3 months) secondary prevention, but a higher bleeding risk should be taken into account.